Compare Stocks: PASG, ANVS, IMMP, and CRDF

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.76 -0.8%	$1.82	$1.54 ▼ $5.50	$60.63M	1.19	768,160 shs	352,313 shs
CRDF Cardiff Oncology	$0.86 +0.5%	$1.27	$0.76 ▼ $3.31	$58.60M	1.44	1.71 million shs	580,341 shs
IMMP Prima BioMed	$0.38 +0.6%	$0.40	$0.29 ▼ $3.53	$56.30M	2.23	254,181 shs	172,916 shs
PASG Passage Bio	$4.47 -0.4%	$5.14	$3.29 ▼ $20.00	$14.34M	1.42	39,961 shs	4,976 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	0.00%	+6.04%	-9.30%	-12.51%	-36.64%
CRDF Cardiff Oncology	0.00%	+3.45%	-32.65%	-49.98%	-65.65%
IMMP Prima BioMed	0.00%	-0.65%	-9.35%	-12.43%	-78.42%
PASG Passage Bio	0.00%	-9.51%	-4.49%	-10.06%	-27.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.76 -0.8%	$1.82	$1.54 ▼ $5.50	$60.63M	1.19	768,160 shs	352,313 shs
CRDF Cardiff Oncology	$0.86 +0.5%	$1.27	$0.76 ▼ $3.31	$58.60M	1.44	1.71 million shs	580,341 shs
IMMP Prima BioMed	$0.38 +0.6%	$0.40	$0.29 ▼ $3.53	$56.30M	2.23	254,181 shs	172,916 shs
PASG Passage Bio	$4.47 -0.4%	$5.14	$3.29 ▼ $20.00	$14.34M	1.42	39,961 shs	4,976 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	0.00%	+6.04%	-9.30%	-12.51%	-36.64%
CRDF Cardiff Oncology	0.00%	+3.45%	-32.65%	-49.98%	-65.65%
IMMP Prima BioMed	0.00%	-0.65%	-9.35%	-12.43%	-78.42%
PASG Passage Bio	0.00%	-9.51%	-4.49%	-10.06%	-27.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.60	Moderate Buy	$11.67	564.77% Upside
CRDF Cardiff Oncology	2.17	Hold	$7.50	776.78% Upside
IMMP Prima BioMed	2.00	Hold	$5.50	1,339.79% Upside
PASG Passage Bio	2.11	Hold	$13.25	196.42% Upside

Current Analyst Ratings Breakdown

Latest PASG, ANVS, IMMP, and CRDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/10/2026	IMMP Prima BioMed	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/6/2026	ANVS Annovis Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	PASG Passage Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/17/2026	IMMP Prima BioMed	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy
6/10/2026	PASG Passage Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral
6/10/2026	PASG Passage Bio	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
6/3/2026	CRDF Cardiff Oncology	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$2.00

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
CRDF Cardiff Oncology	$590K	99.31	N/A	N/A	$0.67 per share	1.28
IMMP Prima BioMed	$6.69M	8.41	N/A	N/A	$0.63 per share	0.61
PASG Passage Bio	N/A	N/A	N/A	N/A	$5.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$28.85M	-$1.71	N/A	N/A	N/A	N/A	-318.08%	-215.47%	8/11/2026 (Estimated)
CRDF Cardiff Oncology	-$45.85M	-$0.67	N/A	N/A	N/A	-8,527.43%	-95.51%	-71.47%	8/4/2026 (Estimated)
IMMP Prima BioMed	-$39.78M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/2/2026 (Estimated)
PASG Passage Bio	-$45.52M	-$11.84	N/A	N/A	N/A	N/A	-150.88%	-59.78%	8/3/2026 (Estimated)

Latest PASG, ANVS, IMMP, and CRDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ANVS Annovis Bio	-$0.44	N/A	N/A	N/A	N/A	N/A
8/4/2026	Q2 2026	CRDF Cardiff Oncology	-$0.1196	N/A	N/A	N/A	$0.06 million	N/A
8/3/2026	Q2 2026	PASG Passage Bio	-$2.27	N/A	N/A	N/A	N/A	N/A
5/15/2026	Q1 2026	ANVS Annovis Bio	-$0.3950	-$0.63	-$0.2350	-$0.63	N/A	N/A
5/14/2026	Q1 2026	CRDF Cardiff Oncology	-$0.13	-$0.18	-$0.05	-$0.18	$0.09 million	$0.04 million
5/12/2026	Q1 2026	PASG Passage Bio	-$2.7640	-$2.36	+$0.4040	-$2.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
IMMP Prima BioMed	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	1.27	1.27
CRDF Cardiff Oncology	N/A	3.27	3.27
IMMP Prima BioMed	N/A	2.97	N/A
PASG Passage Bio	N/A	1.73	1.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
CRDF Cardiff Oncology	16.29%
IMMP Prima BioMed	2.32%
PASG Passage Bio	53.48%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
CRDF Cardiff Oncology	8.50%
IMMP Prima BioMed	3.07%
PASG Passage Bio	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	34.65 million	27.44 million	Optionable
CRDF Cardiff Oncology	20	68.50 million	62.68 million	Optionable
IMMP Prima BioMed	2,021	147.37 million	142.85 million	Optionable
PASG Passage Bio	130	3.21 million	3.05 million	No Data

PASG, ANVS, IMMP, and CRDF Headlines

Recent News About These Companies

Passage Bio (NASDAQ:PASG) Upgraded by Wall Street Zen to "Hold" Rating

August 1 at 1:49 AM | americanbankingnews.com

Insider Buying: Passage Bio (NASDAQ:PASG) Major Shareholder Purchases 50,055 Shares

June 30, 2026 | insidertrades.com

Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

June 25, 2026 | seekingalpha.com

PASG stock slumps 16% after-hours — what’s driving the selloff?

June 24, 2026 | msn.com

Passage Bio and Remix Therapeutics Announce Merger Agreement

June 24, 2026 | markets.businessinsider.com

Passage Bio and Remix Therapeutics Announce Merger Agreement

June 24, 2026 | globenewswire.com

Passage Bio, Inc. résilie son accord de collaboration de recherche avec Gemma Biotherapeutics, Inc

June 3, 2026 | zonebourse.comZ

Passage Bio Ends Key Collaborations and Office Lease

May 27, 2026 | tipranks.com

Passage Bio Shareholders Approve Directors and Executive Pay

May 26, 2026 | tipranks.com

Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?

May 20, 2026 | finance.yahoo.com

Passage Bio (PASG) price target decreased by 62.83% to 11.63

April 28, 2026 | msn.com

TD Cowen downgrades Passage Bio (PASG)

April 23, 2026 | msn.com

Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

April 20, 2026 | globenewswire.com

Passage Bio (PASG) Gets a Buy from Chardan Capital

April 8, 2026 | theglobeandmail.com

Oppenheimer initiates coverage of Passage Bio (PASG) with outperform recommendation

April 1, 2026 | msn.com

Passage Bio (PASG) price target decreased by 22.22% to 31.42

March 28, 2026 | msn.com

Passage Bio advances frontotemporal dementia trial and reports 2025 results

March 10, 2026 | msn.com

Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway

March 10, 2026 | tipranks.com

Analysts Are Bullish on These Healthcare Stocks: Esperion (ESPR), Passage Bio (PASG)

March 8, 2026 | theglobeandmail.com

Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights

March 3, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG, ANVS, IMMP, and CRDF Company Descriptions

Annovis Bio NYSE:ANVS

$1.76 -0.02 (-0.85%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$1.74 -0.01 (-0.80%)

As of 07/31/2026 07:55 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Cardiff Oncology NASDAQ:CRDF

$0.86 +0.00 (+0.52%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.01 (+1.12%)

As of 07/31/2026 07:34 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Prima BioMed NASDAQ:IMMP

$0.38 +0.00 (+0.58%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.38 0.00 (0.00%)

As of 07/31/2026 06:56 PM Eastern

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Passage Bio NASDAQ:PASG

$4.47 -0.02 (-0.45%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$4.50 +0.03 (+0.56%)

As of 07/31/2026 04:10 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PASG, ANVS, IMMP, and CRDF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PASG, ANVS, IMMP, and CRDF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PASG, ANVS, IMMP, and CRDF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG, ANVS, IMMP, and CRDF Company Descriptions

Annovis Bio NYSE:ANVS

Cardiff Oncology NASDAQ:CRDF

Prima BioMed NASDAQ:IMMP

Passage Bio NASDAQ:PASG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PASG, ANVS, IMMP, and CRDF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PASG, ANVS, IMMP, and CRDF Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PASG, ANVS, IMMP, and CRDF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG, ANVS, IMMP, and CRDF Company Descriptions

Annovis Bio NYSE:ANVS

Cardiff Oncology NASDAQ:CRDF

Prima BioMed NASDAQ:IMMP

Passage Bio NASDAQ:PASG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools